Skip to main
LXEO

LXEO Stock Forecast & Price Target

LXEO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lexeo Therapeutics is poised for success with its promising gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases, including the lead candidates LX2006 and LX2020. The company has a strong pipeline with multiple presentations at ASGCT highlighting progress, and a Phase I/II trial demonstrating significant improvement in FA patients. With a diversified portfolio and potential global reach, Lexeo has the potential for high peak sales, making it a solid investment opportunity with a valuation of $17 per share. However, investors must consider the risks associated with the company's focus on AAV-based GT therapies, potential competition, and the need for further financing prior to achieving profitability.

Bears say

Lexeo Therapeutics is a clinical-stage genetic medicine company with a portfolio of gene therapy candidates targeting genetic causes of cardiovascular diseases. While their therapies show promise to address high unmet medical needs, the company faces strong competition, including from companies with advanced clinical programs and multiple GT products for similar indications. Despite some positive clinical data and evidence of sustained or deepening improvements in cardiac and neurological measures, there are still challenges in interpreting the data and demonstrating consistency and differentiation from natural history. Additionally, the company may face regulatory hurdles and may need to raise additional capital before achieving profitability.

LXEO has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexeo Therapeutics Inc (LXEO) Forecast

Analysts have given LXEO a Buy based on their latest research and market trends.

According to 8 analysts, LXEO has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexeo Therapeutics Inc (LXEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.